Possible Mechanisms and Biomarkers of Resistance to Vismodegib in SHH Medulloblastoma
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
AMPK attenuates SHH subgroup medulloblastoma growth and metastasis by inhibiting NF-κB activation.
Cai J, Wang Y, Wang X, Ai Z, Li T, Pu X Cell Biosci. 2023; 13(1):15.
PMID: 36683064 PMC: 9867863. DOI: 10.1186/s13578-023-00963-2.
References
1.
Liang L, Coudiere-Morrison L, Tatari N, Stromecki M, Fresnoza A, Porter C
. CD271 Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma. Cancer Res. 2018; 78(16):4745-4759.
DOI: 10.1158/0008-5472.CAN-18-0027.
View
2.
Thomaz A, Pinheiro K, Souza B, Gregianin L, Brunetto A, Brunetto A
. Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in Medulloblastoma. Front Pharmacol. 2019; 10:698.
PMC: 6606946.
DOI: 10.3389/fphar.2019.00698.
View
3.
Thomaz A, Jaeger M, Brunetto A, Brunetto A, Gregianin L, de Farias C
. Neurotrophin Signaling in Medulloblastoma. Cancers (Basel). 2020; 12(9).
PMC: 7564905.
DOI: 10.3390/cancers12092542.
View
4.
Frappaz D, Barritault M, Montane L, Laigle-Donadey F, Chinot O, Le Rhun E
. MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation. Neuro Oncol. 2021; 23(11):1949-1960.
PMC: 8563312.
DOI: 10.1093/neuonc/noab087.
View
5.
Metcalfe C, de Sauvage F
. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res. 2011; 71(15):5057-61.
DOI: 10.1158/0008-5472.CAN-11-0923.
View